Why Stoke Therapeutics’ Dravet syndrome drug is worth watching

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Stoke Therapeutics is nearing FDA sign-off on a groundbreaking Phase 3 clinical trial designed to prove that its experimental drug for Dravet syndrome, a severe form of epilepsy, can both reduce the frequency of seizures, and for the first time, show an improvement in the cognition and behavior of patients. 

“To show improvement in cognition would set us apart from every other drug that is approved for Dravet. It’s never been done before,” Stoke CEO Ed Kaye told me. 

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$20

for 3 months, then $399/year

$20 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Log In